They have already been systematically excluded from medical trials for cancer treatments. Although 60 per cent of cancers happen in individuals over 65, their participation in clinical trials does not exceed 25 per cent. This has made it tough to predict how older individuals will tolerate and respond to the latest cancer remedies and has offered an obstacle to producing evidence-based medical decisions. Dr Domingo and her co-workers teamed up with experts from the University of Barcelona to look at 224 patients diagnosed with cancerous tumours. The sufferers ranged from 32 to 92 years of age and three-quarters of them were male. Thirty-nine per cent of the patients had been under 65 and 61 percent were 65 or higher. The most typical tumours were respiratory and gastrointestinal . 42 per cent of the sufferers had a localised tumour.Related StoriesAddressing quality of life needs in prostate cancer: an interview with Professor Louis DenisOJ Bio at Medica 2015 – Point of Care diagnostics' role in reducing antibiotics prescribingUsing integrated molecular pathology to manage incidental pancreatic cysts: an interview with Dr Ananya Das The existence of this unique code will simplify the procedure, for both providers and insurers, of submitting and processing claims with respect to their patients, according to Russ DeLonzor, COO and President of Halt Medical, Inc.